Cancel
Kevin Otipoby
Chief Research Officer
@
Seismic Therapeutic
qq9zj.7hh6a7u@6dq3lg553.lu8
Sign up to see email
See Linkedin
Known information
- Has more than 25 years of industry and academia experience in immunology
- Work has largely focused on understanding lymphocyte activation and discovering and developing therapeutics to modulate lymphocyte activity
- Helped start Pandion Therapeutics as the second employee, where he led the Immunology and Biomarker groups
- Built a successful interdisciplinary discovery team at Pandion, which was acquired by Merck in 2021 for $1.85 billion
- Was a key member of the Immunology Pharmacology group at Abbvie, leading the biology efforts to discover a small molecule GPCR agonist with colon-restricted activity to treat IBD
- Led the biology efforts at Biogen to discover and develop small molecule inhibitors of BTK to treat multiple autoimmune diseases and a biologics program targeting long-lived plasma cells
- Is a member of the scientific advisory board of Eurofins Scientific
- Graduated magna cum laude from Washington University in St. Louis with a bachelor’s degree in Molecular Biology and Biochemistry
- Holds a Ph.D. in Immunology from the University of Washington in Seattle
- Did his post-doctoral training in Klaus Rajewsky’s lab at Harvard University
About Seismic Therapeutic
Seismic Therapeutic is a biotech company using machine learning to develop biologics for autoimmune diseases, with a focus on novel enzyme and antibody therapeutics.
Report inaccurate information